Ads
related to: anti il 2 receptor antibodies
Search results
Results from the WOW.Com Content Network
IL-2 binds to the IL-2 receptor, which has three forms, generated by different combinations of three different proteins, often referred to as "chains": α (alpha) (also called IL-2Rα, CD25, or Tac antigen), β (beta) (also called IL-2Rβ, or CD122), and γ (gamma) (also called IL-2Rγ, γ c, common gamma chain, or CD132); these subunits are also parts of receptors for other cytokines.
The IL-2a (CD25, T-cell activation antigen, TAC) is expressed only by the already-activated T lymphocytes. Therefore, it is of special significance to the selective immunosuppressive treatment, and research has been focused on the development of effective and safe anti-IL-2 antibodies.
Types of monoclonal antibodies with other structures than naturally occurring antibodies. The abbreviations in the column Type are as follows: mab: whole monoclonal antibody; Fab: fragment, antigen-binding (one arm) F(ab') 2: fragment, antigen-binding, including hinge region (both arms) Fab': fragment, antigen-binding, including hinge region ...
16183 Ensembl ENSG00000109471 ENSMUSG00000027720 UniProt P60568 P04351 RefSeq (mRNA) NM_000586 NM_008366 RefSeq (protein) NP_000577 NP_032392 Location (UCSC) Chr 4: 122.45 – 122.46 Mb Chr 3: 37.17 – 37.18 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Interleukin-2 (IL-2) is an interleukin, which is a type of cytokine signaling molecule forming part of the immune system. It is a ...
Anti-HER2 antibody. HER2-positive breast cancer, gastric cancer, pancreatic cancer (orphan) and gastro-oesophageal junction cancer. Cardiac dysfunction, infusion-related reactions, peripheral neuropathy and pulmonary toxicity (rare). 2.2 Tyrosine kinase inhibitor: Afatinib: PO: EGFR, HER2 and HER4 inhibitor. Non-small cell lung cancer.
The first approved medication in this class, tocilizumab (Actemra), is an antibody directed against the IL6-receptor. [8] The second, siltuximab (Sylvant), is directed against IL-6 itself. [ 1 ] [ 9 ] Siltuximab is approved for treatment of human immunodeficiency virus-negative and HHV-8 -negative patients with multicentric Castleman's disease .
Ads
related to: anti il 2 receptor antibodies